Synthetic EthR inhibitors boost antituberculous activity of ethionamide - Test2 - elhamkhani - TriplyDB

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

http://www.wikidata.org/entity/Q27655356

about

The application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosis Tuberculosis drug discovery in the post-post-genomic era Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis Crystal structure of a putative transcriptional regulator SCO0520 from Streptomyces coelicolor A3(2) reveals an unusual dimer among TetR family proteins.Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands Kinetic target-guided synthesis in drug discovery and chemical biology: a comprehensive facts and figures survey Targeting Antibiotic Resistance An ethA-ethR-deficient Mycobacterium bovis BCG mutant displays increased adherence to mammalian cells and greater persistence in vivo, which correlate with altered mycolic acid composition Compounds for use in the treatment of mycobacterial infections: a patent evaluation (WO2014049107A1).EthA/R-Independent Killing of Mycobacterium tuberculosis by Ethionamide.Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis.Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.Cyclic di-GMP regulates Mycobacterium tuberculosis resistance to ethionamide MALDI imaging techniques dedicated to drug-distribution studies.Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice.Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery.The mycobacterial cell envelope-lipids [Phenotypic screens or one stone to kill two birds: discover the target and its pharmacological regulator].A structure-guided fragment-based approach for the discovery of allosteric inhibitors targeting the lipophilic binding site of transcription factor EthR.Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis The Non-Essential Mycolic Acid Biosynthesis Genes hadA and hadC Contribute to the Physiology and Fitness of Mycobacterium smegmatis A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.Toxoplasma gondii GRA7-Targeted ASC and PLD1 Promote Antibacterial Host Defense via PKCα Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.Validation of CoaBC as a Bactericidal Target in the Coenzyme A Pathway of Mycobacterium tuberculosis.Antimicrobial treatment improves mycobacterial survival in nonpermissive growth conditions.Tuberculosis drugs: new candidates and how to find more.Emerging biomedical applications of synthetic biology.Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment.Advances In Mycobacterium Tuberculosis Therapeutics Discovery Utlizing Structural Biology.Recycling and refurbishing old antitubercular drugs: the encouraging case of inhibitors of mycolic acid biosynthesis.The TetR family of regulators.Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development.Counterattacking drug-resistant tuberculosis: molecular strategies and future directions.Targeting antibiotic resistance mechanisms in Mycobacterium tuberculosis: recharging the old magic bullets.Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study.

P2860

Q26795478-6C5A4944-A8CD-4E73-86D9-36D1CE0AF087 Q26864729-89882E7B-6C8F-4EA9-B86C-FBC818032EB8 Q27003186-56AB3415-DA30-43F9-A4A4-E66BAC52DB89 Q27668091-6F2B4D57-8C1F-4326-9D5F-8EA4C912B9D3 Q27676092-349EC073-AA41-4B2A-8062-305AEA083B89 Q28072198-9755842D-7869-4F48-A4CD-3EF9A6C22895 Q28078130-6D74F458-85F1-4BD3-8791-15FC31B5C92B Q28659734-3FCC7A90-32E8-41B5-ACF4-990920360A21 Q30907456-4BDD998C-777B-4DB0-BE5A-DA5DA73804AC Q33599760-6DFDB968-BFB7-4F66-BC6B-7BFFA51B08F9 Q33690587-EF8815AD-6472-4D3F-88B8-934C0BD9E5BE Q33810047-8D5FE2A3-5E8A-42EC-AC81-2B874D63E456 Q33905993-FE33A851-456C-4F56-B768-1C002E00ED1D Q33918580-459A728E-39B5-4175-91E8-D47A8A5E5BC5 Q33934400-712D7EC2-9587-4B0C-B392-B9530322E4D2 Q33982151-2991D40A-DA75-4035-9110-B806CC7AD23D Q34153280-F11DF97D-41D1-4B44-82F8-A4A2D540CDC8 Q34355375-3005B604-FB52-43E4-9ED0-9C12F407B7D5 Q35023854-21F493A8-0459-40CB-9B4A-DA65C5CE48D7 Q35061722-40734BD2-32F8-4960-9447-E984BEC97D2D Q35689424-DBA5BD4F-FFFF-4C20-8744-760B908D4A0B Q35877895-28DFCA4F-DEDC-4018-867E-A4379B8A9357 Q35902882-9079B370-7EE4-498E-865F-F706D58A9679 Q36057012-74582245-9518-4FFD-9840-6C360241B7DA Q36261479-3F96BBA0-200E-45F5-B192-431DD0F1E348 Q37403156-783301F2-8170-4CB1-AEE3-0F6FA850BC86 Q37497737-3E51C795-C197-4537-9ED6-B88DF1CC6940 Q37713046-341A6FDD-C463-45A3-8349-8AE8B22EE454 Q37894691-FB1F5A1B-FC95-41EA-AF23-019A068922E6 Q37962354-A89341D0-E7DB-4834-9D91-D3909ED615E1 Q38044744-5F86AE1B-CA8D-412F-89FF-E485AE942000 Q38061197-11260E0F-A242-476E-AC90-CAAB1F8628BC Q38097123-9C408B06-A0C2-4FE2-940D-66E2EC73BA48 Q38134377-07E538AB-A1AF-4434-BB90-A0E4E5B3086F Q38258834-4E277C6F-D5E5-4E21-A8B0-F016EE2FDF32 Q38547598-4EDADD93-0347-453B-8DEB-327CB341291F Q38562670-432BE986-1626-44C6-ACBD-E7A72D57F0E1 Q38661567-7AB685A3-4951-4996-AC43-FF2A72CF8ED6 Q38912109-43E46848-CF59-4B6D-8AA6-7B204E02B707 Q38929849-DB452B67-B757-48DA-B07A-94C9F20C9158

P2860

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

http://www.wikidata.org/entity/Q27655356

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

@ast

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

@en

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

@nl

type

label

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

@ast

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

@en

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

@nl

prefLabel

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

@ast

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

@en

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

@nl

P1433

Q27655356-2C5E64E5-5F76-4A84-879D-A0B0DF02DD03

P1476

Q27655356-A55520D0-F5A1-4727-955E-8DE3376C542D

P2093

Q27655356-1E68038B-4D9D-46F5-A04B-3C0CF0FCFE0C

Q27655356-5D0D78D0-2C20-464A-BE3C-27C52B300F85

Q27655356-5DA5E8C6-3CCB-4C51-B007-3259E0CD40D2

Q27655356-663096B2-B5DE-4C64-9056-315561827A9A

Q27655356-700956F3-1A39-4D6D-A956-322875CAF90D

Q27655356-837C364A-509A-43E8-A30A-CBE05D153341

Q27655356-92A96577-98B3-4298-8C28-8C13DD39AF07

Q27655356-BA2D7FE3-D6CC-4D7B-9487-DEFE532936F5

Q27655356-FCC189D3-D46D-4D90-B4DB-6A9DA59ADA6A

P2888

Q27655356-66BD8A3E-25BA-4100-AF23-E681A88240AE

P304

Q27655356-12D841C5-A2C9-4370-94C9-7A04E0066D0C

P31

Q27655356-B9783D99-2543-41CB-A885-30CBF14C6468

P3181

Q27655356-6854BE30-AD23-4815-ACFD-731CC4F28CFC

P356

Q27655356-046F426D-4D3B-4C43-BA4D-B00D3610AF62

P407

Q27655356-8EB01A67-0157-46AD-9B93-9343140DD646

P433

Q27655356-5AD495B1-2BA9-44AA-B4B6-2CFD6C9F9198

P478

Q27655356-88A5E17C-831E-46B5-BD1E-CF07551D8ED7

P50

Q27655356-0DDAE169-62F4-4D6D-8826-FE5834BE9CD7

Q27655356-40E04F4A-AFF7-46CC-A9CC-D8889AB6188D

Q27655356-53AABA5D-E5FC-4714-87C8-4257202E8DDB

Q27655356-697AA9D5-052D-4FB8-8E0F-CED6F1E18BFD

Q27655356-6986AF5C-B981-4579-8014-C660DA51678A

Q27655356-7C001592-354A-4C2D-9B90-C19638E48B58

Q27655356-D1445040-FF75-4C51-A6F3-AE7FD39034C5

Q27655356-F9582D10-F7A9-4DD8-9D10-2D89A79F95F4

P577

Q27655356-9F005972-B346-4C6D-A1DE-A590B5F351F1

P5875

Q27655356-87001949-D7F9-4F06-A395-19A1EBF281D5

P6179

Q27655356-8C47E5B9-CDCE-413F-9F56-B7B03EC7F3C0

P698

Q27655356-C07712D9-CF5B-42F0-9036-75A24C86366B

P3181

P356

P1433

Nature Medicine

P1476

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

@en

P2093

Amit Singhal

http://www.w3.org/2001/XMLSchema#string

Bertrand Dirié

http://www.w3.org/2001/XMLSchema#string

Eve Willery

http://www.w3.org/2001/XMLSchema#string

Florence Leroux

http://www.w3.org/2001/XMLSchema#string

Frédéric Frénois

http://www.w3.org/2001/XMLSchema#string

Guy Delcroix

http://www.w3.org/2001/XMLSchema#string

Marc Aumercier

http://www.w3.org/2001/XMLSchema#string

Nicolas Willand

http://www.w3.org/2001/XMLSchema#string

Vanessa Mathys

http://www.w3.org/2001/XMLSchema#string

P2888

P304

537-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3324614

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NM.1950

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Matthieu Desroses

Alain R Baulard

Rébecca F Déprez-Poulain

Vincent Villeret

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24398603

http://www.w3.org/2001/XMLSchema#string

P6179

1019311992

http://www.w3.org/2001/XMLSchema#string

P698

19412174

http://www.w3.org/2001/XMLSchema#string